Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record.

EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival

Suo, Zhenhe, Risberg, Bjørn, Kalsson, Mats G., Willman, Kenneth, Tierens, Anne, Skovlund, Eva, Nesland, Jahn M.·2002·The Journal of Pathology

Abstract

One hundred patients with breast carcinoma followed for 7–11 years were included in the present study of EGFR family members, using immunohistochemistry and RT‐PCR. By immunohistochemistry, 36%, 27%, 26%, and 82% of the tumours were positive for EGFR, c‐erbB‐2, c‐erbB‐3, and c‐erbB‐4. All the immunoreactive tumours were confirmed positive by RT‐PCR. Tumour size, histological grade, lymph node status, S‐phase fraction, and stage were confirmed to be significantly associated with both disease‐free and cancer‐specific survival in the present study. Methods of treatment, histological type, and ploidy had no significant effect on survival. Statistical analysis of EGFR family members in these tumours showed a significant association between c‐erbB‐2 expression and reduced disease‐free and cancer‐specific survival. c‐erbB‐4 expression was associated with a more favourable outcome. Co‐expression of c‐erbB‐2 and EGFR was associated with a worse prognosis. c‐erbB‐4 expression, however, showed an antagonistic effect on the clinical influence of c‐erbB‐2 expression. In conclusion, c‐erbB‐2 expression in breast carcinomas is associated with an unfavourable clinical course and EGFR expression has a synergistic effect. However, c‐erbB‐4 antagonizes the c‐erbB‐2 effect on clinical course in breast carcinomas. To achieve best results with immunotherapy against the c‐erbB‐2 receptor, clarifying the status of c‐erbB‐4 expression may be of significance. Copyright © 2001 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.1003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Suo, Z., Risberg, B., Kalsson, M. G., Willman, K., Tierens, A., Skovlund, E., & Nesland, J. M.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2001-10-24
Volume
196
Issue
1
Pages
17-25
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2007435673
Cited by
214
References
0
FWCI
5.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.